ArticleAnnals of hematology2025

Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registries.

Massimo Breccia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.